Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less “go” and more “stop” from the motor striatum for robust therapeutic effects

Stephen M. Stahl

Introduction

Until recently, therapeutic options for tardive dyskinesia (TD) were few and unsatisfactory. The introduction of drugs with a new mechanism of action, namely inhibition of the vesicular monoamine transporter type 2 (VMAT2), is now transforming the treatment of TD.1,2 Here we review dopamine neurotransmission (see also References3–8) and how it is affected by TD and by various drugs to set the stage for the significance of this new breakthrough treatment mechanism.

VMAT2 and Its Inhibition by Tetrabenazine

Transporters for neurotransmitters exist not only on presynaptic nerve terminals (the well-known “reuptake pumps” targeted by most drugs for depression), but also on synaptic vesicles.3 Several types of vesicular transporters have been identified, including different ones for gamma amino butyric acid (GABA), glutamate, glycine, acetylcholine, monoamines, and others.3 The specific transporter known as VMAT2 is located on synaptic vesicles of dopamine, norepinephrine, serotonin, and histamine neurons to store these neurotransmitters until needed for release during neurotransmission.3–7 VMAT2 can also transport certain drugs as “false” substrates, such as amphetamine and ecstasy (MDMA; 3,4-methylenedioxymethamphetamine), which can compete for the “true,” natural neurotransmitter.3,6 Synaptic vesicles create low pH in their lumens (interiors) with an energy-requiring proton pump there.3,6 Low pH in turn serves as the driving force to sequester the neurotransmitter in the synaptic vesicle.3,6

There are actually two types of VMATs: VMAT1, which is localized in both the peripheral and central nervous system (CNS), and VMAT2, located only in the CNS.3–7 There are two known VMAT inhibitors:
reserpine, which inhibits irreversibly both VMAT1 and VMAT2, and tetrabenazine, which reversibly inhibits only VMAT2. That is why reserpine-related drugs, but not tetrabenazine-related drugs, are associated with frequent peripheral side effects, such as orthostatic hypotension (reserpine was once used for hypertension), stuffy nose, itching, and gastrointestinal side effects. Although VMAT2 transports multiple neurotransmitters into synaptic vesicles, tetrabenazine preferentially affects dopamine at clinical doses. When tetrabenazine blocks the transport of dopamine into presynaptic vesicles, dopamine is rapidly degraded by monoamine oxidase (MAO), leading to depletion of presynaptic dopamine proportionate to the degree of VMAT2 inhibition. Tetrabenazine itself is rapidly absorbed and converted into active metabolites, especially alpha and beta hydroxytetrabenazine. Deuterated tetrabenazine is similarly metabolized, but more slowly; valbenazine is converted only into the alpha-hydroxy metabolite.

Treating Overstimulation of D2 Receptors in Tardive Dyskinesia

D2 receptors in the indirect pathway of the motor striatum hypothetically react to chronic blockade by D2 antagonists by “learning” to have tardive dyskinesia with aberrant neuronal plasticity, resulting in supersensitivity to dopamine. This leads to too much inhibition of “stop” signals coming from too much dopamine acting at upregulated D2 receptors in the indirect pathway (on the right), and unopposed “go” signals coming from the direct pathway (on the left), and thus involuntary hyperkinetic movements.
an aberrant attempt to compensate for chronic D2 blockade that results in dopamine overstimulation, then TD would seem to be a disorder ideally set up to respond to interventions that lower dopamine neurotransmission. How can this be done?

One way is to raise the dose of D2 antagonist to block those upregulated supersensitive D2 receptors (Figure 2). This might work in the short term in some patients at the expense of more immediate side effects and the prospects of making TD even worse long term.9 Another treatment possibility is to stop the offending D2 antagonist with the hope that the motor system will re-adjust back to normal and the movement disorder will reverse (Figure 3). Indeed, many patients who do not have an underlying psychotic disorder may be able to tolerate the discontinuation of their D2 antagonist. Unfortunately, it does not seem that the TD brain can “forget” its aberrant neuromodulatory learning very well, and only some patients—particularly those who discontinue D2 blockade soon after the onset of their movements—will enjoy reversal of their TD.9 In fact, most patients experience an immediate worsening of their movements when D2 blockade is eliminated, due to the completely unblocked actions of dopamine in the absence of any D2 antagonist therapy at all (Figure 3).

VMAT2 inhibition is a mechanism that reduces dopamine stimulation without blocking D2 receptors. Thus, this action reduces the overstimulation of D2 receptors in the indirect pathway (on the right in Figure 4), resulting in less inhibition of the stop signal there. However, there is also a benefit of VMAT2 inhibition in the direct pathway where “go” signals are amplified by dopamine at D1 receptors.4,5 Even though these D1 receptors and this direct extrapyramidal pathway may not be the site of pathology in TD,4 they do drive “go” signals for movement,6 and lowering dopamine there by VMAT2 inhibition would thus be expected to lower the “go” signals arising from the direct pathway (Figure 4 on the left).4 Combined with
more “stop” signals from the indirect pathway (Figure 4 on the right), motor output to drive abnormal involuntary hyperkinetic movements is therefore robustly reduced by this combination of effects of dopamine depletion in both pathways.

So, it appears that VMAT2 inhibition can “train” motor pathways of TD to compensate for their abnormal “learning” after chronic D2 receptor blockade.\(^1,2,4,7\) Whether this will be disease modifying in the long run, and whether it will reverse rather than only treat movements symptomatically, must be determined by long-term studies of VMAT2 inhibition in TD.

### Variable in Treating TD with VMAT2 Inhibition

Treating TD is not going to be simple (Figure 5). That is, there will be a balancing act between the need to continue D2 blockade, which caused TD in the first place (Figure 1), to increase its dose (Figure 2), or whether the D2 blocker can be discontinued (Figure 3). All these choices will affect the impact of dopaminergic stimulation on the symptoms of TD differently, and thus will affect the dose of VMAT2 inhibitor and degree of VMAT2 inhibition needed in a given patient.

However, even this is not the whole story. Since VMAT2 inhibition is reversible, the amount of inhibition in a given patient at a given dose will be dependent upon the concentration of dopamine in the presynaptic neuron (Figure 5).\(^3\) Dopamine levels can be affected by drugs (such as amphetamine and MAO inhibitors) and disease state (such as stress, psychosis, and depression).\(^3\) The degree of VMAT2 inhibition required for a given patient also depends upon several variables on the postsynaptic neurons receiving dopamine stimulation (Figure 5). That is, the number and sensitivity (and possible reversibility) of supersensitive D2 receptors will vary from one patient to another, with time, and in

### Figure 3. Discontinuing D2 blockers in tardive dyskinesia. Sometimes it is necessary or desirable to discontinue the D2 antagonist causing TD in the hope that the motor system will re-adjust back to normal and the movement disorder will reverse. Sometimes the underlying disorder will not allow that. However, if it is possible to discontinue D2 antagonist treatment, it is unfortunately uncommon that the movement disorder reverses. In fact, most patients experience an immediate worsening of their movements when D2 blockade is eliminated, due to the completely unblocked actions of dopamine in the absence of any D2 antagonist therapy at all.
different areas of the motor striatum, depending upon which body parts are most affected. The degree of dopamine reduction caused by VMAT2 inhibition that is needed by a given patient will also vary with which specific D2 blocker is given, and at which dose, and with how much dopamine is being released into the synapse. Changes in psychosis status, mood, and other factors will change dopamine levels in the synapse and therefore the amount of VMAT2 inhibition required. That is, dopamine can compete with any D2 blocker administered, but this depends quite widely on which blocker is given (affinities for the D2 receptors have a broad range), and at which dose. Thus, the skilled clinician must balance these factors when administering a VMAT2 inhibitor to attain best results in the individual patient. When done well, there are very good prospects for robust improvements in TD in many patients.

References:

